Back

Vericiguat in heart failure patients: analyzing safety, tolerability, and quality of life via meta-analysis of randomized controlled trials

31 August 2024 (13:00 - 13:40)
Organised by: Logo
Congress Presentation Part of: Heart failure: drug therapy and multidisciplinary care Pharmacotherapy ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Assistant Professor Lokman Hekim Tanriverdi

Inonu University, Malatya (Turkiye)

6 More presentations in this session

Presentation thumbnail
Beta-blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction
Doctor S. Matsumoto (Tokyo, JP)
Abstract Slides Video
Presentation thumbnail
Systematic review and meta-analysis on the effects of physical activity-based interventions on frailty status and clinical outcomes in adults with long-term cardiac conditions.
Ms H. Waterhouse (Leicester, GB)
Abstract Slides Video
Presentation thumbnail
Assessing the practicality of a novel heart failure therapeutic score (QUAD Score) for drug optimisation in heart failure with a reduced ejection fraction
Doctor A. Ganapathy (Basildon, GB)
Abstract Slides Video
Presentation thumbnail
Short-term effects on sacubitril/valsartan therapy on right ventricle work and mechanics in patients with heart failure and reduced ejection fraction
Doctor J. Ottela (Turku, FI)
Abstract Slides Video
Presentation thumbnail
Cardiovascular mortality with oral potassium-binders in patients with CKD and heart failure
Doctor H. Barzkar (Dallas, US)
Abstract Slides Video

Access the full session

Session thumbnail
Heart failure: drug therapy and multidisciplinary care

The Event

Event poster

ESC Congress 2024

31 August 2024 13:00 CET
You may be interested in
thumbnail
Congress Presentation
Vericiguat in a real-world heart failure population: a single-centre experience
thumbnail
Congress Presentation
Soluble guanylate cyclase in heart failure: A network meta-analysis and subgroup analyses of reduced and preserved ejection fraction.
thumbnail
Congress Presentation
Use of vericiguat: real-world outcomes and insights from the VERITA registry.

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources